We're looking to buy more of this chip stock as the once-hot group cools

Stocks were mixed as the Nasdaq slipped slightly on weakness in semiconductor names (Micron, Intel, Broadcom), while investors made room for SK Hynix’ Nasdaq debut. Intel was down over 3% and nearly 10% on the week, but Jim Cramer framed the pullback as an opportunity tied to AI-driven CPU demand transitioning from training to inference. Near-term catalysts are set for earnings next week—Wells Fargo (needs improvement), Goldman Sachs (investment banking updates), and Johnson & Johnson (core cancer/multiple myeloma sales plus newer therapies)—but the article is largely positioning/recap without concrete new numbers.

Analysis

The immediate signal is more about positioning than a fresh fundamental shock: investors are trimming crowded semiconductor exposure and favoring names with clearer near-term monetization. That creates a relative tailwind for INTC if the market believes inference-driven CPU demand can offset slower training-related capex, but the bigger second-order winner could be the foundry/equipment ecosystem only if Intel’s execution actually turns into wafer starts and outsourced packaging orders over the next 6-18 months. By contrast, memory peers like MU are vulnerable to any capital rotation away from U.S. semis, even if the underlying cycle remains constructive.

Into earnings, GS has a cleaner setup than WFC because deal activity can translate into fee leverage faster than bank NII can reaccelerate. WFC remains the weakest link: if the quarter does not show expense discipline plus credit stability, the market will likely keep assigning it a low-quality multiple and treat it as a value trap rather than a rebound story. For JNJ, the defensive bid matters less than the durability of newer product growth; if core pharma can offset patent erosion, the stock can keep rerating as a low-volatility cash compounder.

The contrarian view is that the semis selloff may be overstated if it is just a pre-earnings/risk-rebalance move before a large listing and not a sign of deteriorating end demand. What would falsify the bullish INTC view is another quarter of margin dilution or no evidence that inference demand is lifting server CPU share; for WFC, continued flat-to-down guidance on net interest income or a pickup in charge-offs would keep the thesis broken. Over the next 1-3 months, earnings outcomes matter more than the morning headline, and the market will likely reward evidence over narratives.

Key Decisions for Investors

• Add to INTC only on weakness, but keep it small: tactical long for a 1-3 month window into evidence of inference-related CPU mix improvement; stop if management does not show margin stabilization or foundry utilization traction next quarter.
• Avoid chasing MU here; consider MU as a relative short versus INTC or versus a broader semi basket if the rotation persists, since memory is the most sensitive to sentiment-driven de-risking even when fundamentals are stable.
• Enter a modest long JNJ / short WFC pair into next week’s earnings: JNJ has the cleaner downside protection and WFC has the highest bar to prove operating leverage; revisit if WFC shows meaningful NII or expense upside.
• Stay neutral to underweight GS ahead of earnings unless IB commentary is clearly accelerating; if deal pipelines merely remain 'good,' upside is likely capped and the stock can fade on any mild miss.
• If INTC breaks to new weekly lows without follow-through in foundry or server guidance, cut the long thesis and rotate into defensive healthcare proxies like JNJ rather than averaging down.